# John McHutchison

> John McHutchison, AO, MD is the CEO and Chairman of Tune Therapeutics, a pioneering epigenome editing company based in Durham, NC. An internationally acclaimed hepatologist and drug developer, McHutchison spent nearly a decade at Gilead Sciences as Chief Scientific Officer, where he led the development of transformative hepatitis C cures used by over 3.2 million people worldwide, including Sovaldi and Harvoni. Now at Tune, he is steering the company's TEMPO epigenome editing platform toward a new era of precision medicine for chronic and complex diseases.

- **Role:** CEO and Chairman at Tune Therapeutics
- **Organizations:** Tune Therapeutics, Assembly Biosciences, Comanche Biopharma, Gilead Sciences, Duke University Medical Center, Scripps Clinic and Research Foundation
- **From:** Australia
- **Nationality:** Australian
- **Education:** Bachelor of Medicine and Bachelor of Surgery (MBBS), University of Melbourne, Residency in Internal Medicine; Fellowship in Gastroenterology, Royal Melbourne Hospital, Post-doctoral Fellowship in Liver Diseases, University of Southern California, Member, Royal Australasian College of Physicians
- **Known for:** Led development of five marketed therapies for chronic Hepatitis B and Hepatitis C, used by over 3.2 million people worldwide, Spearheaded NDA submissions and launches of Sovaldi, Harvoni, and Epclusa at Gilead Sciences - achieving >95% HCV cure rates, Served as Gilead Sciences' Chief Scientific Officer and Head of R&D

## Career timeline

- **1990s** — Post-doctoral fellowship in liver diseases at University of Southern California; Assistant Professor of Medicine at USC
- **1990s-2000s** — Nearly 10 years at Scripps Clinic and Research Foundation, La Jolla, CA - Medical Director of Liver Transplantation and Director of GI/Hepatology
- **2000s-2010** — Associate Director at Duke Clinical Research Institute; Director of GI/Hepatology Research Program; Professor of Medicine, Duke University Medical Center
- **2010** — Joined Gilead Sciences as Senior Vice President, Liver Disease Therapeutics
- **2014** — Harvoni (sofosbuvir/ledipasvir) launched, achieving >95% cure rates for Genotype 1 HCV
- **2018** — Appointed Gilead's Chief Scientific Officer and Head of Research & Development; Appointed Officer of the Order of Australia (AO)
- **2019** — Left Gilead Sciences after nearly a decade; Joined Assembly Biosciences as President and CEO
- **2020** — Received Advance Global Impact Award
- **2022** — Retired as CEO of Assembly Biosciences; remained as Director and Science & Technology Committee Chair
- **2025-03** — Appointed CEO and Chairman of the Board at Tune Therapeutics
- **2025-12** — Appointed Chairman and Director of Comanche Biopharma Australia

## Achievements

- Led development of five marketed therapies for chronic Hepatitis B and Hepatitis C, used by over 3.2 million people worldwide
- Spearheaded NDA submissions and launches of Sovaldi, Harvoni, and Epclusa at Gilead Sciences - achieving >95% HCV cure rates
- Served as Gilead Sciences' Chief Scientific Officer and Head of R&D
- Appointed Officer of the Order of Australia (AO) in 2018 for distinguished service to medical research in gastroenterology and hepatology
- Published more than 300 peer-reviewed scientific articles and abstracts
- Instrumental in Gilead's strategic acquisition of Kite Therapeutics, establishing leadership in CAR-T cell therapy
- Recipient of Advance 2020 Global Impact Award
- Adjunct Professor at Duke University Department of Medicine
- Led Assembly Biosciences as President and CEO (2019-2022)

## Latest updates

- **2025-03** — Appointed CEO and Chairman of the Board at Tune Therapeutics
- **2025-01** — Tune Therapeutics completed over $175M Series B financing, led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation
- **2025-12** — Appointed Chairman and Director of Comanche Biopharma Australia

## Links

- Website: https://tunetx.com
- LinkedIn: http://www.linkedin.com/in/john-mchutchison

---

Profile page: https://yespress.io/john-mchutchison
Published by YesPress — https://yespress.io
Last updated: 2026-05-16